论文部分内容阅读
２０３例肺癌中（鳞癌１１０例，腺癌６３例，小细胞癌１１例，鳞腺癌７例，肺泡腺癌６例，类癌３例，粘液细胞癌３例）上皮生长因子受体（ＥＧＦＲ）阳性占５０．２５％，Ｐａｎ－ｒａｓ阳性占４１．８７％，Ｐ５３阳性为３５．４７％。ＥＧＦＲ和Ｐ５３同时表达占的２４．６３％。ｃ－ｅｒｂＢ－２阳性者在１１０例鳞癌中为２２．７３％，而在６３例腺癌中为５２．３８％，两者有非常显著的差异（Ｐ＜０．０１）。Ｐ５３的表达与患者的生存率和无远处转移率有关，Ｐ５３阴性的发生远处转移危险性为Ｐ５３阳性的２．３５倍（Ｐ＝０．００７）。
203 lung cancer cases (110 squamous cell carcinoma, 63 adenocarcinoma, 11 small cell carcinoma, 7 squamous cell carcinoma, 6 alveolar adenocarcinoma, 3 carcinoid, 3 mucinous cell carcinoma) epithelial growth factor receptor ( EGFR (positive) accounted for 50.25%, Pan-ras positive accounted for 41.87%, P53 positive was 35.47%. EGFR and P53 were simultaneously expressed in 24.63%. The positive rate of c-erbB-2 was 22.73% in 110 cases of squamous cell carcinoma and 52.38% in 63 cases of adenocarcinoma. There was a very significant difference between the two groups (P<0.01). The expression of P53 was related to the survival rate of patients and no distant metastasis rate. P53-negative risk of distant metastasis was 2.35 times that of P53-positive (P=0.007).